echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Roche 2021 semi-annual report: revenue of 30.7 billion Swiss francs in China, 2.9 billion Swiss francs

    Roche 2021 semi-annual report: revenue of 30.7 billion Swiss francs in China, 2.9 billion Swiss francs

    • Last Update: 2021-07-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On July 22, Roche released the 2021 semi-annual report, with total revenue of 30.













    Roche's heavyweight bispecific antibody Hemlibra (imicelizumab) has covered all types of hemophilia patients.




    Attached table: Sales of Roche's main products in 2020 (100 million Swiss francs)



    Original title: Roche's 2021 semi-annual report: revenue of 30.
    7 billion Swiss francs, China's 2.
    9 billion Swiss francs, PD-L1 increased by 29%, and Iimerizumab increased by 45%

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.